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Abstract
Objective: An important aspect of perioperative care in pediatric cardiac surgery is maintenance
of optimal hemodynamic status using vasoactive/inotropic agents. Conventionally, this has
focused on maintenance of cardiac output rather than perfusion pressure. However, this approach
has been abandoned in our center in favor of one focusing primarily on perfusion pressure, which
is presented here and compared to the conventional approach.
Design: A retrospective study.
Setting: Regional center for congenital heart disease. University Hospital of Lausanne,
Switzerland.
Patients: All patients with Aristotle risk score 8 that underwent surgery from 1996 to 2012
were included. Patients operated between 1996 and 2005 (Group 1: 206 patients) were treated
according to the conventional approach. Patients operated between 2006 and 2012 (Group 2:
217 patients) were treated according to our new approach.
Interventions: All patients had undergone surgery for correction or palliation of congenital cardiac
defects.
Outcome measurements: Mortality, duration of ventilation and inotropic treatment, use of
ECMO, and complications of poor peripheral perfusion (need for hemofiltration, laparotomy for
enterocolitis, amputation).
Results: The two groups were similar in age and complexity. Mortality was lower in group 2 (7.3%
in group 1 vs 1.4% in group 2, P< .005). Ventilation times (hours) and number of days on inotro-
pic/vasoactive treatment (all agents), expressed as median and interquartile range [Q1–Q3] were
shorter in group 2: 69 [24–163] hours in group 1 vs 35 [22–120] hours in group 2 (P< .01) for
ventilation, and 9 [3–5] days in group 1 vs 7 [2–5] days in group 2 (P< .05) for inotropic/vasoac-
tive agents. There were no differences in ECMO usage or complications of peripheral perfusion.
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Conclusions: Results in pediatric cardiac surgery may be improved by shifting the primary focus of
perioperative care from cardiac output to perfusion pressure.
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1 | INTRODUCTION
Perioperative care in pediatric cardiac surgery has many facets. One of
the crucial facets is the maintenance of optimal hemodynamic status
using various vasoactive and inotropic agents. Conventionally, this has
focused primarily on maintenance of adequate cardiac output rather than
perfusion pressure.1–9 However, this approach has been abandoned in
our center in favor of one focusing primarily on perfusion pressure. This
new approach is presented here and compared to the conventional one.
2 | MATERIALS AND METHODS
This study was approved by our institutional review board (Ethics’ com-
mittee of the University Hospital of Lausanne, Switzerland), which
agreed that no informed consent from patients or their relatives was
required. All authors had full access to all data included in this study,
and take responsibility for its integrity.
2.1 | Our conventional approach
A conventional approach, focusing on maintenance of cardiac output,
was used in our center for many years. Cardiac output was maintained
by optimizing its three major contributing factors—preload, cardiac
function, and afterload reduction. Cardiac function, in turn, was opti-
mized by three measures: (1) stimulating/supporting systole (contractil-
ity) with beta stimulants and by maintaining adequate serum
concentrations of ionized calcium, (2) prevention of arrhythmias by
maintaining adequate levels of potassium and magnesium, and (3) facili-
tating diastole (relaxation) with lusitropic agents.
In terms of beta stimulation, dopamine6 dobutamine were used
as first-choice agents at dosages of 5–10 lg/kg/min each. If this
proved insufficient for maintenance of cardiovascular stability, epi-
nephrine was added, usually starting at dosages of 0.1–0.2 lg/kg/min.
Isoproterenol was also used on occasion, especially if acceleration of
heart rate was desired. Dobutamine and isoproterenol are also potent
vasodilators, thus also generating afterload reduction.
Serum concentrations of ionized calcium were maintained slightly
high: 1.3–1.4 mmol/L. This was achieved with the administration of
intravenous boluses of calcium chloride in the operating room after ter-
mination of cardiopulmonary bypass and as routine three-times-daily
boluses on the ICU. On rare occasions, a continuous infusion was used
instead, especially in small babies who particularly benefit from calcium.
Likewise, magnesium chloride boluses were administered three times a
day aiming to maintain serum concentrations no less than 0.7 mmol/L.
This treatment with both calcium and magnesium was continued until
patients started eating. Potassium levels were maintained no lower
than 4.0 mmol/L.
In terms of lusitropy, on the other hand, all patients received milri-
none (or amrinone early in our experience) at a dose of 0.75 lg/kg/
min, with a starting loading dose of 50 lg/kg administered on cardio-
pulmonary bypass after removal of the aortic cross-clamp. These
agents are also vasodilators. Therefore, they also fulfill the function of
afterload reduction. Milrinone, in particular, has been found to signifi-
cantly improve results in pediatric cardiac surgery.10
Conversely, norepinephrine was used much less frequently, since
it is a strong vasoconstrictor and a weak beta stimulant. It was certainly
never used as first-choice agent. This agent was used as a last resource
in cases of refractory vasoplegia in patients that were already on high
doses of other inotropic agents.
This treatment regime was adjusted in situations where cardiac
dysfunction was thought to be mainly diastolic, and also in cases of val-
var dysfunction. In diastolic dysfunction, the adjustment was in using
less beta stimulants and relying more on a lusitropic agent. Using less
beta stimulants results in less tachycardia as well, which is also benefi-
cial in diastolic dysfunction. Tachycardia should also be avoided in
cases of valvar stenosis. In valvar regurgitation, however, a degree of
tachycardia may be allowed in conjunction with inotropic support and
afterload reduction; all three actions may be generated with dobut-
amine or isoproterenol.
This treatment was monitored, and dosages adjusted, according to
markers of adequate cardiac output—urine output, serum lactate levels,
and mixed venous saturations.
2.2 | Our new approach
Our new approach shares most components of the conventional
approach, including maintenance of adequate preload, cardiac function
and afterload reduction, and monitoring the same indices of adequacy
of cardiac output. However, it differs in two important respects: (1) in
the form of optimizing cardiac function and (2) in the management of
afterload reduction.
With respect to optimizing cardiac function, the new approach
gives more weight to diastole than systole. To this effect, it minimizes
beta stimulation while relying on lusitropic agents. In other words, it
does what the conventional approach indicates for diastolic dysfunc-
tion, except that it does this in every case.
With respect to afterload reduction, this is usually achieved with
the vasodilatory effect of lusitropic agents, and also low-dose
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dopamine (too low for beta stimulation, but sufficient for DA1 receptor
stimulation with possibly associated renal and gastrointestinal protec-
tion), although more potent vasodilators may be added if needed. How-
ever, independently of which vasodilator is used, the effect is closely
monitored so that perfusion pressure (defined as mean arterial pressure
minus central venous pressure) and specifically diastolic pressure are
not compromised. These two pressures are maintained no lower than:
 35 mm Hg in premature neonates
 40 mm Hg in neonates born at term
 50 mm Hg in infants and young children
 60 mm Hg in older children and adolescents
Although these pressures are slightly higher than those seen in health,
they are helpful postoperatively in order to secure tissue perfusion in
the face of the inevitable generalized edema caused by cardiopulmonary
bypass.
With the above differences and criteria in mind, the new mode of
treatment may be presented as follows:
1. Dobutamine and isoproterenol have been abandoned completely.
2. The use of epinephrine has been reduced dramatically. It is used in
only two circumstances: (1) as boluses during the management of
cardiac arrest, (2) preoperatively in patients in severe cardiogenic
shock, while preparations are being made for urgent surgery and/
or to establish mechanical circulatory support.
3. Calcium, magnesium, and potassium levels are maintained in
exactly the same way, and with the same target serum concentra-
tions, as in the conventional approach described above.
4. All patients receive a low but fixed dose of dopamine at 3 lg/kg/
min.
5. All patients also receive milrinone at 0.75 lg/kg/min after a load-
ing dose of 50 lg/kg on cardiopulmonary bypass after removal of
the aortic cross-clamp, as in the conventional approach.
6. A stronger vasodilator than milrinone and low-dose dopamine
may be added to the treatment if afterload remains too high, that
is, if blood pressure remains too high, especially if pulse pressure
is low. In such cases, we use sodium nitroprusside, the dose of
which is titrated to reduce blood pressure down to the above-
mentioned target levels, but no lower. If pressures drop below
these levels, this agent is stopped, but milrinone and dopamine are
maintained at the above-mentioned infusion rates.
7. If perfusion pressure and/or diastolic pressure are lower than the
target levels, norepinephrine is administered (again, without stop-
ping milrinone and low-dose dopamine) provided this does not
violate our bedside safety criterion for vasoconstriction (see
below). The dose of norepinephrine is titrated to achieve the tar-
get pressures. The commonest doses used are 0.1–0.4 lg/kg/min,
but much higher doses are also used occasionally. Conversely, in
cases where pressures do not drop below the target levels, this
agent would not be needed at all.
8. Norepinephrine will have no effect in the very rare instances
where patients have been taking phenoxybenzamine (as treatment
of pulmonary hypertension). In such patients, norepinephrine is
substituted with vasopressin.
2.3 | Our safety criterion for vasoconstriction
Vasoconstriction, regardless of whether this is with norepinephrine or
vasopressin, would be unsafe in two circumstances: (1) when forward
flow during diastole is compromised, (2) in the presence of aortopulmo-
nary collateral arteries and/or surgical shunts.
Diastolic forward flow may be checked by arterial waveform analy-
sis—specifically looking at the shape of the diastolic phase of the arte-
rial pressure curve. Arterial waveform analysis should, however, be
regarded as only a guide rather than a hard and fast rule, since it is sub-
ject to inaccuracies, for example, due to damping. Nevertheless, with
FIGURE 1 Arterial pressure curves illustrating how these may be
used to verify the presence of forward flow during diastole. The
dotted double-headed arrow indicates the diastolic phase. A. The
diastolic phase has a slope (it is not flat). This indicates that there
is diastolic forward flow, the amount of which is represented by
the area under the diastolic curve (delineated by the horizontal
dotted arrow and the vertical dotted line). In such circumstances,
norepinephrine may be used safely, even at high doses. B. The dia-
stolic phase is flat, indicating that there is little or no forward flow
during diastole. This is typically seen in hypovolemia and is a warn-
ing sign that norepinephrine should not be used. C. If norepineph-
rine is used when the diastolic curve is flat, it may worsen the
hemodynamic situation by causing some retrograde diastolic flow.
This is seen as a small upstroke (shown by the solid black arrow)
on the diastolic curve
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such limitations in mind, a diastolic pressure curve that has a slope (i.e.,
is not flat) indicates that forward flow is maintained during diastole, the
amount of which is represented by the area under that part of the
curve (Figure 1A). Therefore, norepinephrine may be used safely, even
at high doses, in the absence of aortopulmonary collateral arteries or
surgical shunts.
Conversely, a flat diastolic curve (Figure 1B) indicates that there is
little forward flow during diastole and that norepinephrine should not
be used. This is typically seen in hypovolemia requiring volume admin-
istration. Volume administration restores the slope of the diastolic
pressure curve, and norepinephrine may then be used if needed. If nor-
epinephrine is administered in the presence of a flat diastolic pressure
curve, the hemodynamic situation is worsened such that there may be
an element of retrograde blood flow during diastole. This will be mani-
fested as a small upstroke on the diastolic pressure curve (Figure 1C).
Norepinephrine, however, also provides venoconstriction and thus may
potentiate preload until normovolemia is fully restored. Therefore, it
may be useful in conjunction with volume replacement.
A flat diastolic pressure curve may also be seen when there is an
important steal from the aorta, namely in severe aortic valvar regurgita-
tion, and this would also contraindicate vasoconstriction. But this situa-
tion would be unusual after corrective surgery.
Other sources of aortic steal, namely aortopulmonary collateral
arteries and surgical shunts, deserve a special mention. These condi-
tions do not usually result in a flat diastolic curve, since the steal is not
usually severe enough. In this respect, therefore, they allow vasocon-
striction if needed. However, they also do require careful balancing of
pulmonary and systemic circulations (Qp/Qs) within narrow limits. This
balance may be disturbed by vasoconstriction, which may augment
aortic steal and cause excessive pulmonary blood flow (i.e., augment
Qp/Qs). Precisely for this reason, such cases particularly benefit from
afterload reduction. Overall, any manipulation of vascular tone in these
circumstances, both vasodilatation and vasoconstriction, must be
titrated cautiously so that the pursuit of target pressures does not shift
Qp/Qs outside acceptable limits of balance.
2.4 | Patient groups
Data from all patients operated in our center from 1996 to 2012 were
examined. Throughout this period, the surgical team and principal anes-
thesiologist and intensive care specialist remained the same, as did the
protocols of conduct of cardiopulmonary bypass and myocardial
protection.
Although the full spectrum of operations for congenital heart dis-
ease are carried out in our center, only patients that had undergone
operations with moderate or high risk were included in this study. Sur-
gical risk was assessed according to the Aristotle score.11 An Aristotle
score of 8 was arbitrarily chosen as the cut-off point; only patients
with a score of 8 or more were included in this study. These represent
approximately one-third of our total workload.
Patients with an Aristotle score of 8 or more were divided into two
groups. Group 1 consists of patients operated between 1996 and 2005
when our conventional perioperative approach was used. Group 2 con-
sists of patients operated between 2006 and 2012 when the new
approach was used. The two groups were compared with respect to:
 Hospital mortality.
 Ventilation times (via endotracheal tube, that is, not counting nonin-
vasive ventilation).
 The duration of treatment with inotropic and/or vasoactive agents.
 Use of ECMO.
 Complications of low peripheral perfusion: Necessity of hemofiltra-
tion, laparotomy for enterocolitis, and amputation.
2.5 | Statistical analysis
Quantitative data are expressed as median and interquartile range
[Q1–Q3]. Qualitative data are expressed as percentages. The one-
sample Kolmogorov-Smirnov test showed that the distribution of data
was not normal. Therefore, the statistical significance of differences
between the two groups was assessed by the Mann-Whitney U test
for quantitative data and Chi square test for qualitative data. These
tests were carried out with PASW 18. Differences were considered sig-
nificant at P< .05.
3 | RESULTS
Our findings are presented in Table 1. In summary, the two groups are
comparable with respect to age and case complexity. However, our
new approach (group 2) is associated with significantly lower mortality,
ventilation times and duration of treatment with inotropic/vasoactive
agents. On the other hand, there were no statistically significant differ-
ences with respect to the use of ECMO or the complications of poor
peripheral perfusion (hemofiltration, laparotomy for enterocolitis, and
amputation).
There was one case of lower limb amputation in group 1. This was
a three-year-old boy with tetralogy of Fallot that was surgically cor-
rected in 1997. He suffered from thrombosis of his femoral artery, pos-
sibly caused by a femoral arterial catheter.
4 | DISCUSSION
Pediatric cardiac surgery and its perioperative care have developed so
much that good results are the norm. Nevertheless, results may be fur-
ther improved by shifting the primary focus of perioperative care from
cardiac output to perfusion pressure.
Conventionally, perioperative care in pediatric cardiac surgery
has been based on the concept that what really matters is cardiac
output rather than perfusion pressure. This is reflected in the publi-
cations on this subject, which describe strategies for optimizing
stroke volume and cardiac output while blood pressure is hardly
ever mentioned.1–9 Accordingly, the conventional approach puts
strong emphasis on enhancement of systole, since this is a potent
way of increasing cardiac output. However, this clashes with
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developments in our understanding of cardiac physiology in the last
two decades whereby we have realized the dominant role of dias-
tole in cardiac function and dysfunction. This major paradigm shift is
explained in several exhaustive review articles.12–21 In broad terms,
however, it may be summarized very briefly in terms of the ener-
getics of the cardiac cycle.
The cardiac cycle is governed by the actin–myosin cross-bridge
cycle, which depends on calcium fluxes into and out of the cytosol.
Calcium entry into the cytosol (during the plateau phase of the action
potential in systole) does not require energy. Its exit during diastole,
however, consumes a great deal of energy (ATPase pump activity) and is
a slower process. This makes relaxation a slow process, thus maintaining
some tone throughout diastole that resists over-distension in response
to filling, that is, some cross-bridging takes place at all times. These fea-
tures make relaxation a very active process to the extent that diastole
consumes much more energy, and is much more vulnerable, than sys-
tole. Diastole suffers more and earlier at times of low energy availability
(hypoxia and/or ischemia). In addition, diastolic dysfunction eventually
leads to systolic dysfunction. This is because, if the heart does not fill
well, myocytes will not reach optimal length prior to systole, and will
contract less well (Starling’s law). Nevertheless, diastole is the limiting
factor in cardiac function—one can have diastolic dysfunction without
systolic dysfunction, but not vice versa. By the time systolic dysfunction
begins to appear, diastolic dysfunction is already well established.
This crucial and pivotal role of diastole had remained hidden for a
long time probably because, unlike systolic dysfunction, diastolic dys-
function is difficult to detect and quantify. Nevertheless, it does sug-
gest strongly that cardiac care should focus primarily on diastole.
The conventional approach does provide diastolic care with lusi-
tropic agents. But it also boosts systole substantially with beta stimula-
tion and afterload reduction. This is the problem with focusing on
cardiac output—it forces you to enhance systole. In doing so, the con-
ventional approach acquires the following drawbacks:
1. It jeopardizes myocardial perfusion by reducing both diastolic
pressure (consequence of afterload reduction) and diastolic time
(due to tachycardia caused by beta stimulation, which also harms
diastole).
2. It further discriminates against myocardial perfusion since the
enhanced blood flow generated by this strategy is mainly systolic,
being driven by beta stimulation. This contributes little to myocar-
dial perfusion, which is mainly a diastolic phenomenon, even in
the right ventricle if hypertrophied.
3. Beta stimulation increases the metabolic demand of the myocar-
dium significantly.5,6 Thus the heart would require much more cor-
onary blood flow than usual, which it may not receive since this is
already compromised.
4. Beta stimulation also increases the metabolic demand of the rest
of the body. Therefore, the already-struggling heart has to work
even harder to cater to this.
Overall, the conventional approach secures tissue perfusion (cardiac
output) at the heart’s expense. It forces the heart to serve the rest
of the body when the heart itself is recovering from major surgery
and needs care. This is a fundamental flaw. It led us to adopt an
alternative approach that gives at least equal priority to the heart
(specifically diastole). This was implemented with the following
considerations:
1. Unlike for systolic dysfunction, there are not many ways of treat-
ing diastolic dysfunction, other than lusitropic agents, which
should remain in place.
2. Apart from this, we can help the heart in only two ways: (1) By
securing good myocardial perfusion, (2) By minimizing factors that
would increase its metabolic demand and that of the rest of the
body, that is, avoiding beta stimulation.
TABLE 1 Patient characteristics and perioperative and postoperative data
Variables examined Group 1 Group 2 P value
Number of patients 206 (including 29 neonates) 217 (including 23 neonates)
Age (years) 3 [0.6–7] 3.5 [0.9–6] NS
Aristotle score 9 [8–10] Full range: 8 - 14.5 9 [8–10.3] Full range: 8 - 14.5 NS
Bypass times (minutes) 122 [99–157] 128 [103–160] NS
Mortality 15 cases (7.3%) 3 cases (1.4%) <.005
Ventilation times (hours) 69 [24–163] 35 [22–120] <.01
Inotropic (all agents) times (days) 9 [3–5] 7 [2–5] <.05
Use of ECMO 8 cases (3.9%) 5 cases (2.3%) NS
Use of hemoﬁltration 4 cases (1.9%) 1 case (0.46%) NS
Limb amputation 1 case (0.5%) 0 NS
Laparotomy for enterocolitis 1 case (0.5%) 0 NS
Results are expressed as percentages or medians and interquartile range [Q1–Q3]. Where a difference between the two groups is not statistically sig-
nificant, this is reported as NS
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3. To secure myocardial perfusion, we must maintain adequate per-
fusion pressure (and specifically diastolic pressure) and diastolic
time, that is, avoid excessive afterload reduction and tachycardia.
4. Adequate perfusion pressure also favors peripheral tissue perfu-
sion, both directly and by improving systemic venous return (i.e.,
preload), which improves cardiac output.22
5. Afterload reduction may be achieved with the vasodilatory effect
of lusitropic agents and low-dose dopamine, or more potent vaso-
dilators may be added. However, the effect must not be such that
diastolic and perfusion pressures drop below the levels required
for adequate tissue (including coronary) perfusion. If this happens,
the dose must be reduced, or the agent stopped altogether. If the
vasodilator being used should continue because of its other bene-
fits (lusitropic agents), norepinephrine should be added to rectify
pressures. The overall management is a balance between vasodila-
tation and vasoconstriction, being guided by diastolic and perfu-
sion pressures.
This is why we abandoned dobutamine and isoproterenol—both are
potent vasodilators and beta stimulants, and cause tachycardia. This is
also why calcium chloride is used for contractility; it does not increase
the metabolic demand of the whole body and does not cause
tachycardia.
Such focus on perfusion pressure, and its consequent liberal use of
norepinephrine, although unusual in pediatric cardiac surgery, is not
new to adult intensive care where it is greatly appreciated, including in
cardiac surgery in some centers. In fact, norepinephrine is now often
the first choice agent in the treatment of critically ill adults. This started
with the treatment of septic shock,23 but later extended to other areas
including hepatorenal syndrome24 and even cardiogenic shock.25–29
Interestingly, these clinical scenarios are extreme forms of the same
pathophysiology seen after cardiac surgery with cardiopulmonary
bypass. The similarity with cardiogenic shock is obvious, but septic
shock is just as close an analogy. Indeed, the pathophysiology inflicted
by cardiopulmonary bypass is practically indistinguishable from that of
septic shock, including myocardial dysfunction found in both scenarios
in response to inflammatory mediators.30,31
Norepinephrine may raise two concerns: First, that it may jeop-
ardize peripheral perfusion, and that some organs may be sensitive
to this—limbs, brain, kidneys,32 and the gastrointestinal system.33,34
Second, that its advantage of assisting myocardial perfusion may be
undermined and outweighed by increasing afterload thus harming
cardiac function. With respect to the first concern, peripheral perfu-
sion is not ignored by our new approach; on the contrary, it is sup-
ported with adequate perfusion pressure and moderated afterload
reduction. This is reflected in our results with respect to peripheral
perfusion, which are favorable. Furthermore, peripheral perfusion
has not been an issue in any of the above-mentioned publications
on the use of norepinephrine.22–28 In addition, gastrointestinal
mucosal perfusion seems unaffected by norepinephrine after cardiac
surgery in adults.35 Likewise, cerebral oxygen saturation seems unaf-
fected by this agent during cardiopulmonary bypass in adults.36
With respect to the second concern, vasoconstriction is enforced
only to the extent of achieving minimum acceptable physiological
perfusion pressures, that is, the infusion rate of norepinephrine is
meticulously adjusted and calibrated, using syringe drivers that allow
adjustments of 0.1 mL/h, to achieve precisely those pressures and
no more. This does not generate anywhere near enough afterload to
harm cardiac function.18,37
This study excluded patients operated prior to 1996 and after
2012 in order to eliminate several confounding factors, especially in
making sure the principal care team members and protocols of car-
diopulmonary bypass and myocardial protection remained the same
throughout the study period (these changed at these two dates). In
addition, prior to 1996, our unit was improved in several ways: (1)
the introduction of nitric oxide and ECMO, (2) optimizing the nutri-
tional protocol,38 and (3) improving the sedation protocol, especially
with respect to midazolam, which has potent negative cardiovascu-
lar effects.39 Indeed, the dose of midazolam was significantly
reduced to 0.04–0.12 mg/kg/h. If this proves insufficient, clonidine
is added. After 2012, on the other hand, apart from the surgical
team changing, milrinone was replaced with levosimendan in some
high-risk cases.
This study has important limitations. It is retrospective, non-
randomized, and its control group is historical. Although we took all
measures that we could to guard against the impact of era on
results, we cannot eliminate this possibility. Another limitation is
that its endpoints are crude (mortality, ventilation times, etc.). This
is always a problem with retrospective studies where choice is
limited—finer endpoints such as mixed venous saturations, lactate
levels, and cerebral saturations were not available consistently. We
are tempted to state that cerebral saturations do not drop as moni-
tored by near-infrared spectroscopy, but this tool was not available
early in our experience, nor is it clear that this is the best neuro-
monitoring method.40
5 | CONCLUSIONS
Despite the above-mentioned limitations, focus on perfusion pressure
does appear to produce excellent results. This is reflected in a signifi-
cantly reduced mortality without additional complications related to
vasoconstriction, bearing in mind that vasoconstriction is carefully
titrated and limited to physiological parameters. This has been our
standard and exclusive approach since 2006.
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